LensGen, Inc.

6 articles about LensGen, Inc.

• LensGen® Receives IDE Approval from the U.S. FDA to Begin Clinical Study of the Juvene® Presbyopia-Correcting Intraocular Lens

  11/29/2021

  LensGen, Inc. announced today that it has received approval for an Investigational Device Exemption (IDE) from the U.S. Food and Drug Administration (FDA) to initiate a pivotal study of the company's Juvene intraocular lens (IOL) for patients with cataracts.

• LensGen® Closes $10 Million Financing and Welcomes James V. Mazzo to its Board of Directors

  8/20/2020

  LensGen, Inc., an ophthalmic medical device company and developer of Juvene®, a disruptive fluid-optic intraocular lens for cataract and presbyopia treatment, announces the initial Closing of a $10 million of the $20 million Bridge Financing.

• LensGen® Announces Presentations and Scientific Papers on Juvene™ in Paris

  9/10/2019

  LensGen®, Inc. will be featured in several activities as the European Society for Cataract and Refractive Surgery (ESCRS) event in Paris, France begins.

• LensGen® Will Present Early Results Of International "Grail" Study At ASCRS

  4/30/2019

  Eric Donnenfeld M.D. Chosen for Prestigious Innovators Lecture

• LensGen Announces Funding And Patent Success

  7/17/2018

  LensGen®, Inc. is reporting significant progress in its effort to transform how presbyopia is addressed.

• SoCal's LensGen Bags $21 Million to Advance Modular, Fluid-Optic Accommodating Intraocular Lens

  5/2/2017